National Bank of Canada’s Capricor Therapeutics CAPR Stock Holding History

National Bank of Canada’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$265	Buy	+11	New	+$334	﹤0.01%	2936
2026 Q1	–	Sell	-143,500	Closed	-$4.14M	–	2995
2025 Q4	$4.14M	Sell	143,500 -254,200	-64%	-$3.32M	﹤0.01%	910
2025 Q3	$2.87M	Buy	397,700 +229,000	+136%	+$1.69M	﹤0.01%	1006
2025 Q2	$1.68M	Buy	+168,700	New	+$1.78M	﹤0.01%	1182

Other funds holding CAPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

National Bank of Canada's CAPR Position: Q2 2026 in Review

National Bank of Canada opened a new position in Capricor Therapeutics (CAPR) in Q2 2026: 11 shares worth $265. The stake represents ﹤0.01% of the portfolio and ranks #2936 among its holdings. This is a return to the name: National Bank of Canada previously reported a position in CAPR as recently as Q4 2025.

National Bank of Canada first reported a position in CAPR in Q2 2025 and has held it in 4 quarters since. The position peaked at $4.14M in Q4 2025. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

National Bank of Canada held 11 shares of Capricor Therapeutics worth $265 as of Q2 2026.
Capricor Therapeutics was a new National Bank of Canada position in Q2 2026.
Capricor Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q2 2026, its #2936 holding.
National Bank of Canada first reported a position in Capricor Therapeutics in Q2 2025 and has held it in 4 quarters since.
National Bank of Canada's Capricor Therapeutics position peaked at $4.14M in Q4 2025.
169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.